Cancer Cell Int. 2026 Jan 12. doi: 10.1186/s12935-025-04080-7. Online ahead of print.
ABSTRACT
BACKGROUND: Gastric cancer (GC) remains a major global health challenge, characterized by high morbidity and mortality rates. Early diagnosis is essential for improving patient outcome. This study aims to develop a diagnostic model based on specific signature genes by investigating the association between double-negative (DN) T cells and GC.
METHODS: A bidirectional Mendelian randomization (MR) analysis was conducted to assess the causal relationship between immune cell phenotypes and GC pathogenesis. Three machine learning (ML) algorithms, combined with logistic regression, were employed to identify featured genes. Real-world cohorts and animal experiments were applied to validate the expression levels of DN T cells and selected model genes. Virtual screening was further performed to identify potential therapeutic candidates.
RESULTS: DN T cells were identified as significant risk factors for GC. A diagnostic model incorporating four genes-EML4, IL32, FXYD5, and TTC39C-was constructed using ML algorithms and demonstrated high predictive accuracy across multiple clinical cohorts. External validation and experimental analyses confirmed elevated DN T cell levels and increased expression of all model genes in GC tissues, correlating with poor prognosis. Virtual screening identified potential therapeutic compounds with strong binding affinity to target proteins, indicating their potential for GC treatment.
CONCLUSIONS: The study established a novel diagnostic model for GC based on DN T cell signature genes, which shows robust predictive performance and significant clinical benefit. The findings underscore the important role of DN T cells and model genes in GC, providing new insights into early diagnosis and potential therapeutic targets for effective management of GC.
PMID:41526926 | DOI:10.1186/s12935-025-04080-7
